A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MADRS / Montgomery-Asberg Depression Rating Scale

[Related PubMed/MEDLINE]
Total Number of Papers: 1495
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MADRS  (>> Co-occurring Abbreviation)
Long Form:   Montgomery-Asberg Depression Rating Scale
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia. C-SSRS, CDSS, PANSS, TD, TEAEs, YMRS
2019 47 Sustained Functional Recovery and Symptom Remission After Maintenance Treatment with Aripiprazole Once-Monthly for Patients with Bipolar I Disorder. AEs, AOM 400, BP-I, CGI-BP-S, FAST, YMRS
2019 50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results. ADTs, AEs, MDD, SIB
2019 67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder. TD, YMRS
2019 77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia. AIMS, BL, C-SSRS, CDSS, MD, PANSS, SZD, TD, TEAEs, VMAT2, YMRS
2019 A bi-factor model of the Montgomery Asberg depression rating scale and future cognitive impairments in older adults: A 6-year follow-up study. SNAC-K
2019 A novel approach for assessing neuromodulation using phase-locked information measured with TMS-EEG. ECT, MDD, PLF, PLV, TMS-EEG
2019 A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder. QIDS-SR, SDQ, SPCD
2019 A pilot study of brexpiprazole for bipolar depression. QoL.BD
10  2019 A prenatal supplement with methylfolate for the treatment and prevention of depression in women trying to conceive and during pregnancy. MDD
11  2019 A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. CGI, LIFE-RIFT, NAC, Q-LES-Q-SF, SOFAS
12  2019 A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. ADTs, TEAE
13  2019 Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). AKSTP-TRD, BDNF, GEE, HAM-D, TRD
14  2019 Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. 5D-ASC, MDD, NMDA
15  2019 Audio-digital recordings for surveillance in clinical trials of major depressive disorder. MDD
16  2019 Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C. IFN-alpha, MDD
17  2019 Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3). BUP/SAM
18  2019 Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study. CGI-S
19  2019 Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. OR
20  2019 Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. CSFQ-14, MDD, MDEs, SSRI, TESD
21  2019 Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study. ANCOVA, MDD
22  2019 Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. TEAEs
23  2019 Differences in Speed of Response of Depressive Symptom Dimensions in Older Persons During Electroconvulsive Therapy. ECT
24  2019 Disentangling the association of depression on the anti-fatigue effects of ketamine. MDD, NIH-BFI
25  2019 Double-blind, randomized pilot clinical trial targeting alpha oscillations with transcranial alternating current stimulation (tACS) for the treatment of major depressive disorder (MDD). DLPFC, hdEEGs, MDD, tACS
26  2019 Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression. TAU, TRD
27  2019 Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. MDD, SSRI, TCA
28  2019 Effect of Sertraline, Dosulepin, and Venlafaxine on Non-BDNF Neurotrophins in Patients With Depression: A Cohort Study. BDNF, NGF, NT-3, NT-4, NTs
29  2019 Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. BDI, VNS
30  2019 Electroconvulsive Therapy Modulates Resting-State EEG Oscillatory Pattern and Phase Synchronization in Nodes of the Default Mode Network in Patients With Depressive Disorder. ACC, CSD, DMN, ECT, EEG, eLORETA, FP, IPL, MMSE, PCC, ROIs
31  2019 Enhancing the efficacy of integrative improvisational music therapy in the treatment of depression: study protocol for a randomised controlled trial. IIMT, LH, RFB
32  2019 Functional connectivity predictors of acute depression treatment outcome. FC, fMRI, ROI
33  2019 High-Intensity Aerobic Exercise Acutely Increases Brain-derived Neurotrophic Factor. AEX, BDNF, HI, HRR, IP, LO
34  2019 Impact of subjective vs. objective remission status on subjective cognitive impairments in depression. J-PDQ, QIDS
35  2019 Improvement in depression with oestrogen treatment in women with schizophrenia. ANCOVA, PANSS
36  2019 Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression. ALFF, dmPFC, FC, FDR, LLD, MDD, ROI, SSRIs, vmPFC
37  2019 Irregular eating patterns associate with hypomanic symptoms in bipolar disorders. BD, YMRS
38  2019 Is there enough "interest in and pleasure in" the concept of depression? The development of the Leuven Affect and Pleasure Scale (LAPS). HDRS, LAPS
39  2019 Leaky gut biomarkers in depression and suicidal behavior. HC, I-FABP, IL-6, MDD, rSA, SUAS
40  2019 Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures. AEDs, ESL, FS, ITT, OL, QOL, SAEs, SSF, TEAEs
41  2019 Low- and high-dose aripiprazole augmentation and plasma levels of homovanillic acid in major depressive disorder: A randomized, open-label study. HD, LD, pHVA
42  2019 Magnitude of Reduction and Speed of Remission of Suicidality for Low Amplitude Seizure Therapy (LAP-ST) Compared to Standard Right Unilateral Electroconvulsive Therapy: A Pilot Double-Blinded Randomized Clinical Trial. ECT, LAP-ST, MDE, pLAP-ST, RUL, SI
43  2019 Neurognitive function and symptom remission 2 years after ECT in major depressive disorders. ECT, EMQ, MCCB
44  2019 Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life. OCS, PANSS, Y-BOCS
45  2019 Predictors of response and remission in a naturalistic inpatient sample undergoing multimodal treatment for depression. ---
46  2019 Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. ---
47  2019 Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. AEs, ER, MDD
48  2019 Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. TRD
49  2019 Repetitive Transcranial Magnetic Stimulation with Resting-State Network Targeting for Treatment-Resistant Depression in Traumatic Brain Injury: A Randomized, Controlled, Double-Blinded Pilot Study. DAN, DMN, RSNM, rTMS, TBI
50  2019 SIGMA-VB: Validity and reliability of the Brazilian Portuguese version of the Montgomery-Asberg Depression Rating Scale using the Structured Interview Guide for the MADRS. AIUNI, HAM-D, SIGMA, SIGMA-VB
51  2019 Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. ---
52  2019 Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial. DBS, slMFB, TRD
53  2019 Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report. LEAPS, MDD, QIDS-SR, SDS
54  2019 The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: A randomized placebo-controlled study. LMERM, NAC
55  2019 The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder. MDD, SDS, SHAPS, THINC-it
56  2019 Vagus Nerve Stimulation for Depression: A Systematic Review. MD, RR
57  2019 Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. CID, DSST, MDD, PDQ-20, UPSA
58  2019 [Cognitive disorders in Behcet's disease]. BD, CD, HAM-A, MD
59  2019 [Erratum to: Effectiveness and tolerability of electroconvulsive therapy : Influence of clinical response from the patient's point of view]. ECT
60  2018 A Double-Blind, Randomized, Placebo-Controlled Study of Aspirin and N-Acetylcysteine as Adjunctive Treatments for Bipolar Depression. NAC, NSAIDs
61  2018 A longitudinal study on deep brain stimulation of the medial forebrain bundle for treatment-resistant depression. DBS, MFB, TRD
62  2018 A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. ---
63  2018 A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder. DESV, MMT
64  2018 A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression. ITT
65  2018 A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder. ADT, MDD, SDS
66  2018 Acupuncture for depression. CCMD-CTR, CIs, HAM-D, ICD, KISS, KMbase, MD, OASIS, RDC, RISS, RRs, SMDs
67  2018 Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression. fMRI, LLD, MDD, ROC
68  2018 Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study. HAM-A
69  2018 Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). CGI-S, GAF-F, GAF-S, MES, NAC, YMRS
70  2018 Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study. ADT, AEs, CGI-S, MDD, SASS, TEAE
71  2018 Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. MDD, SAMe, SNPs
72  2018 Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. ADs, SUD, TRD
73  2018 Anxiety Symptoms in Older Adults with Depression Are Associated with Suicidality. CDT, GAI, MMSE, PSMS
74  2018 Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression. MDD
75  2018 Are self-report scales as effective as clinician rating scales in measuring treatment response in routine clinical practice? CUDOS, HAM-D, MIDAS, QIDS-SR
76  2018 Assessing depression severity with a self-rated vs. rater-administered instrument in patients with epilepsy. RCTs
77  2018 Associations between symptoms of depression and heart rate variability: An exploratory study. BDI, HRV, LF, MDD
78  2018 Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. CES-D, CGI-I, CGI-S, GI-DQ, HAM-D, IBS-QOL, MDD, mESS
79  2018 BDNF and NRG1 polymorphisms and temperament in selective serotonin reuptake inhibitor-treated patients with major depression. BDNF, GLM, NRG1, NS, RD
80  2018 C-reactive protein and response to lurasidone in patients with bipolar depression. CRP, wr-CRP
81  2018 Cardiorespiratory fitness and response to exercise treatment in depression. CRF
82  2018 Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. ADT, CGI-I, LSMD, MDD, SDS
83  2018 Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. Q-LES-Q-SF, QOL, TRD
84  2018 Circadian Rhythm Sleep-Wake Disorders Predict Shorter Time to Relapse of Mood Episodes in Euthymic Patients With Bipolar Disorder: A Prospective 48-Week Study. BD, CRSWDs, YMRS
85  2018 Clinical correlates of negative health events in a research sample with epilepsy. ED, ESES, ESMS, ESS, MSPSS, NHEs
86  2018 Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study. HAM-D, MDD, SGAs
87  2018 Clinical validation of the Psychotic Depression Assessment Scale (PDAS) against independent global severity ratings in older adults. CGI-S, PDAS
88  2018 Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. WBC
89  2018 Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases. ADD, BD, cDMARDs, HADS, HAM-A, pSS, RA, RD, SLE, SSc
90  2018 Deep brain stimulation of the supero-lateral branch of the medial forebrain bundle does not lead to changes in personality in patients suffering from severe depression. DBS, NEO-FFI, TRD
91  2018 Dehydroepiandrosterone and dehydroepiandrosterone sulfate levels in combat veterans with or without a history of suicide attempt. DHEA, DHEAS
92  2018 Depressive symptoms in obesity: Relative contribution of low-grade inflammation and metabolic health. hs-CRP, MINI
93  2018 Differences in the dynamics of changes in the concentration of kynurenic acid in the blood serum of depressed patients treated with electroconvulsive therapy. CGI, ECT, KYNA, NMDA
94  2018 Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression. PSD
95  2018 Effect of electroconvulsive therapy on brain-derived neurotrophic factor levels in patients with major depressive disorder. BDNF, ECT, MDD
96  2018 Effect of Low Frequency Repetitive Transcranial Magnetic Stimulation on Depression and Cognition of Patients with Traumatic Brain Injury: A Randomized Controlled Trial. rTMS, SCWT, TMT
97  2018 Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial. MDD
98  2018 Effects of 5-aminolevulinic acid supplementation on home-based walking training achievement in middle-aged depressive women: randomized, double-blind, crossover pilot study. ALA, IWT, PLC, SFC
99  2018 Effects of personality on the association between paroxetine plasma concentration and response. TCI
100  2018 Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. ADT, MDD, SDS